HC Wainwright Expects Lower Earnings for Aligos Therapeutics

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Aligos Therapeutics in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($2.53) per share for the quarter, down from their previous forecast of ($2.36). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2026 earnings at ($2.59) EPS, Q3 2026 earnings at ($1.72) EPS, Q4 2026 earnings at ($1.76) EPS, FY2026 earnings at ($8.25) EPS, FY2027 earnings at ($4.06) EPS, FY2028 earnings at ($3.02) EPS, FY2029 earnings at ($2.61) EPS and FY2030 earnings at ($1.06) EPS.

A number of other analysts have also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group began coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $35.00.

Aligos Therapeutics Price Performance

NASDAQ:ALGS opened at $7.30 on Monday. Aligos Therapeutics has a one year low of $3.76 and a one year high of $13.69. The company’s 50-day simple moving average is $7.64 and its 200 day simple moving average is $8.92. The firm has a market capitalization of $45.19 million, a P/E ratio of -0.85 and a beta of 2.67.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%.

Institutional Trading of Aligos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. grew its holdings in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at about $215,000. SummitTX Capital L.P. purchased a new stake in shares of Aligos Therapeutics in the 4th quarter worth approximately $1,299,000. Verition Fund Management LLC purchased a new stake in shares of Aligos Therapeutics in the 4th quarter worth approximately $664,000. Finally, Marshall Wace LLP bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $2,504,000. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.